Gene therapy strategies for tumor antiangiogenesis

Hwai Loong Kong, Ronald Crystal

Research output: Contribution to journalReview article

165 Citations (Scopus)

Abstract

Based on the concept that solid tumors cannot grow without the generation of new blood vessels, there is growing interest in the use of antiangiogenesis agents to inhibit tumor growth. This review summarizes the concepts of using gene transfer vectors to provide high concentration of antiangiogenic proteins within an organ. While there are many challenges that must be met before antiangiogenesis can be used to effectively treat human tumors, gene transfer strategies have the potential to provide sustained, high, local concentrations of antiangiogenic mediators specifically targeted to organs containing tumors, minimizing systemic toxicity. Antiangiogenesis gene therapy strategies will most likely be effective in a state of low tumor burden, where this 'genetic tourniquet' can provide trans (i.e., acting in the extracellular milieu as opposed to within tumor cells) suppression of the growth of endothelial cells in the milieu of micrometastases.

Original languageEnglish
Pages (from-to)273-286
Number of pages14
JournalJournal of the National Cancer Institute
Volume90
Issue number4
DOIs
Publication statusPublished - 18 Feb 1998
Externally publishedYes

Fingerprint

Genetic Therapy
Neoplasms
Tourniquets
Neoplasm Micrometastasis
Growth
Tumor Burden
Genes
Blood Vessels
Endothelial Cells
Proteins

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Gene therapy strategies for tumor antiangiogenesis. / Kong, Hwai Loong; Crystal, Ronald.

In: Journal of the National Cancer Institute, Vol. 90, No. 4, 18.02.1998, p. 273-286.

Research output: Contribution to journalReview article

@article{58e13c3c71f34eb8879ffc377f39b77b,
title = "Gene therapy strategies for tumor antiangiogenesis",
abstract = "Based on the concept that solid tumors cannot grow without the generation of new blood vessels, there is growing interest in the use of antiangiogenesis agents to inhibit tumor growth. This review summarizes the concepts of using gene transfer vectors to provide high concentration of antiangiogenic proteins within an organ. While there are many challenges that must be met before antiangiogenesis can be used to effectively treat human tumors, gene transfer strategies have the potential to provide sustained, high, local concentrations of antiangiogenic mediators specifically targeted to organs containing tumors, minimizing systemic toxicity. Antiangiogenesis gene therapy strategies will most likely be effective in a state of low tumor burden, where this 'genetic tourniquet' can provide trans (i.e., acting in the extracellular milieu as opposed to within tumor cells) suppression of the growth of endothelial cells in the milieu of micrometastases.",
author = "Kong, {Hwai Loong} and Ronald Crystal",
year = "1998",
month = "2",
day = "18",
doi = "10.1093/jnci/90.4.273",
language = "English",
volume = "90",
pages = "273--286",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "4",

}

TY - JOUR

T1 - Gene therapy strategies for tumor antiangiogenesis

AU - Kong, Hwai Loong

AU - Crystal, Ronald

PY - 1998/2/18

Y1 - 1998/2/18

N2 - Based on the concept that solid tumors cannot grow without the generation of new blood vessels, there is growing interest in the use of antiangiogenesis agents to inhibit tumor growth. This review summarizes the concepts of using gene transfer vectors to provide high concentration of antiangiogenic proteins within an organ. While there are many challenges that must be met before antiangiogenesis can be used to effectively treat human tumors, gene transfer strategies have the potential to provide sustained, high, local concentrations of antiangiogenic mediators specifically targeted to organs containing tumors, minimizing systemic toxicity. Antiangiogenesis gene therapy strategies will most likely be effective in a state of low tumor burden, where this 'genetic tourniquet' can provide trans (i.e., acting in the extracellular milieu as opposed to within tumor cells) suppression of the growth of endothelial cells in the milieu of micrometastases.

AB - Based on the concept that solid tumors cannot grow without the generation of new blood vessels, there is growing interest in the use of antiangiogenesis agents to inhibit tumor growth. This review summarizes the concepts of using gene transfer vectors to provide high concentration of antiangiogenic proteins within an organ. While there are many challenges that must be met before antiangiogenesis can be used to effectively treat human tumors, gene transfer strategies have the potential to provide sustained, high, local concentrations of antiangiogenic mediators specifically targeted to organs containing tumors, minimizing systemic toxicity. Antiangiogenesis gene therapy strategies will most likely be effective in a state of low tumor burden, where this 'genetic tourniquet' can provide trans (i.e., acting in the extracellular milieu as opposed to within tumor cells) suppression of the growth of endothelial cells in the milieu of micrometastases.

UR - http://www.scopus.com/inward/record.url?scp=0032542528&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032542528&partnerID=8YFLogxK

U2 - 10.1093/jnci/90.4.273

DO - 10.1093/jnci/90.4.273

M3 - Review article

C2 - 9486813

AN - SCOPUS:0032542528

VL - 90

SP - 273

EP - 286

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 4

ER -